ArticleJACC. Basic to translational science2020
Genetic and In Vitro Inhibition of
2 registry-linked trialsOpen access · goldAbstract read
In one paragraph
Article in JACC. Basic to translational science, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 51 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed, 1 pooled it
9.6field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized Trial of PCSK9 Inhibitors in Calcific Aortic Valve Stenosis
NCT07256197 phase3not yet recruitingnot on this mapstarted 2026, after this paper: background citation
Effect and Safety of PCSK9 Inhibitors on the Progression of Mild/Middle Calcific Aortic Stenosis: A Randomized Controlled Clinical Trial
Who cites it
51 citing papers in PubMed, 1 synthesis or guideline pooled it, 90 citations in OpenAlex.
- Pooled it
- Article
- PCSK9 Inhibitors and Risk of Aortic Stenosis in Atherosclerotic Cardiovascular Disease.JACC. Advances · 2026Article
- PRMT3-Mediated Arginine Methylation Stabilizes PCSK9 to Promote Aortic Valve Calcification.Circulation · 2026Article
- Metabolic Drivers of Valve Calcification and Atrial Remodeling in Calcific Aortic Stenosis.Biomolecules · 2026Review
- LDL receptor-independent mechanisms of proprotein convertase subtilisin/kexin type 9 in cardiovascular pathophysiology.Frontiers in cardiovascular medicine · 2026Review
- Rationale and Design of the EPISODE Trial: A Randomized Controlled Trial on the Effect of PCSK9 Inhibitors in Calcific Aortic Valve Stenosis.Journal of the American Heart Association · 2025Article
- Genetic insights into causal effects of lipids and lipid-modifying targets on calcific aortic valve stenosis: a Mendelian randomized study.Scientific reports · 2025Article
- Unraveling the Link Between Aortic Stenosis and Atherosclerosis: What Have We Learned?Medicina (Kaunas, Lithuania) · 2025Review
- RNA interference versus antibody-based PCSK9 inhibition for the prevention of cardiovascular disease: a drug-target Mendelian randomization study.Cardiovascular research · 2025Article
- Navigating the Landscape of Translational Medicine of Calcific Aortic Valve Disease: Bridging Bench to Bedside.JACC. Asia · 2025Review
- Regulatory roles of PIWI-interacting RNAs in cardiovascular disease.American journal of physiology. Heart and circulatory physiology · 2025Review
- 2025 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association.Circulation · 2025Review
- Calcific aortic stenosis: omics-based target discovery and therapy development.European heart journal · 2025Review
- Atherosclerosis, calcific aortic valve disease and mitral annular calcification: same or different?International journal of cardiology · 2025Review
- Bibliometric analysis of treatment modalities in calcific aortic valve stenosis.Frontiers in pharmacology · 2025Article
- Rare Genetic Variants inCirculation · 2024Article
- Current Management and Therapy of Severe Aortic Stenosis and Future Perspective.Journal of atherosclerosis and thrombosis · 2024Review
- Genetic proxy of lipid-lowering drugs and calcific aortic valve stenosis: A Mendelian randomization study.Heliyon · 2024Article
- Aortic Valve Calcium Score: Applications in Clinical Practice and Scientific Research-A Narrative Review.Journal of clinical medicine · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
29 authors at 16 institutions in 8 countries.
Nicolas PerrotCentre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Québec, Québec, Canada.
Vincenza ValerioCentro Cardiologico Monzino IRCCS, Milan, Italy.
Donato MoschettaCentro Cardiologico Monzino IRCCS, Milan, Italy.
S Matthijs BoekholdtDepartment of Cardiology, Academic Medical Center, Amsterdam, the Netherlands.
Christian Dinal'Institut du thorax, INSERM, CNRS, UNIV Nantes, CHU Nantes, Nantes, France.
Hao Yu ChenMcGill University Health Center Research Institute, Montreal, Québec, Canada.
Erik AbnerEstonian Genome Center, Institute of Genomics, University of Tartu, Tartu, Estonia.
Andreas MartinssonDepartment of Cardiology, Clinical Sciences, Lund University and Skåne University Hospital, Lund, Sweden.
Hasanga D ManikpurageCentre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Québec, Québec, Canada.
Sidwell Rigadel'Institut du thorax, INSERM, CNRS, UNIV Nantes, CHU Nantes, Nantes, France.
Romain Capouladel'Institut du thorax, INSERM, CNRS, UNIV Nantes, CHU Nantes, Nantes, France.
Elvira MassUniversity of Bonn, Developmental Biology of the Innate Immune System, Life & Medical Sciences Institute (LIMES), Bonn, Germany.
Marie-Annick ClavelCentre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Québec, Québec, Canada.
Thierry Le Tourneaul'Institut du thorax, INSERM, CNRS, UNIV Nantes, CHU Nantes, Nantes, France.
David Messika-ZeitounDepartment of Cardiology, Assistance Publique - Hôpitaux de Paris, Bichat Hospital, Paris, France.
Nicholas J WarehamDepartment of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom.
James C EngertMcGill University Health Center Research Institute, Montreal, Québec, Canada.
Gianluca PolvaniCentro Cardiologico Monzino IRCCS, Milan, Italy.
Philippe PibarotCentre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Québec, Québec, Canada.
Tõnu EskoEstonian Genome Center, Institute of Genomics, University of Tartu, Tartu, Estonia.
J Gustav SmithDepartment of Cardiology, Clinical Sciences, Lund University and Skåne University Hospital, Lund, Sweden.
Patrick MathieuCentre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Québec, Québec, Canada.
George ThanassoulisMcGill University Health Center Research Institute, Montreal, Québec, Canada.
Jean-Jacques Schottl'Institut du thorax, INSERM, CNRS, UNIV Nantes, CHU Nantes, Nantes, France.
Yohan BosséCentre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Québec, Québec, Canada.
Marina CameraCentro Cardiologico Monzino IRCCS, Milan, Italy.
Sébastien ThériaultCentre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Québec, Québec, Canada.
Paolo PoggioCentro Cardiologico Monzino IRCCS, Milan, Italy.
Benoit J ArsenaultCentre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Québec, Québec, Canada.
Institut Universitaire de Cardiologie et de Pneumologie de Québec · CACentro Cardiologico Monzino · ITMcGill University Health Centre · CAUniversité Laval · CAInserm · FRInstitut du Thorax · FRUniversity of Tartu · EEAcademic Medical Center · NLCentre National de la Recherche Scientifique · FRLund University · SESkåne University Hospital · SEUniversity of Bonn · DEUniversity of Cambridge · GBUniversity of Milan · ITUniversity of Naples Federico II · ITUniversity of Ottawa · CA
Funding
Molecular and Genetic Epidemiology of Lp(a)-mediated Calcific Aortic Valve DiseaseR01HL128550 · NHLBI · MCGILL UNIVERSITY HEALTH CTR RES INST · PI THANASSOULIS, GEORGE · 2017 to 2020
$1.7MCancer Research UK 14136Medical Research Council G1000143Medical Research Council MC_UU_00006/1Medical Research Council MC_UU_12015/1NHLBI NIH HHS R01 HL128550
Abstract
The authors investigated whether PCSK9 inhibition could represent a therapeutic strategy in calcific aortic valve stenosis (CAVS). A meta-analysis of 10 studies was performed to determine the impact of the
Indexed as
Ad DMEM, advanced Dulbecco’s modified Eagle’s mediumaortic valve interstitial cellapoB, apolipoprotein Bapolipoprotein BCAD, coronary artery diseasecalcific aortic valve stenosisCAVS, calcific aortic valve stenosisHDL-C, high-density lipoprotein cholesterolIQR, interquartile rangeLDL cholesterolLDL-C, low-density lipoprotein cholesterollipoprotein(a)Lp(a), lipoprotein(a)PBS, phosphate-buffered salinePBST, 1× phosphate-buffered saline with 0.1% TritonPCSK9, proprotein convertase subtilisin/kexin type 9proprotein convertase subtilisin/kexin type 9SNP, single nucleotide polymorphismTC, total cholesterolVIC, valve interstitial cellVLDL-C, very-low-density lipoprotein cholesterolwGRS, weighted genetic risk score
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
NCT04968509ClinicalTrials.gov
NCT07256197ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.